Avience Biomedicals (NSE:AVIENCE) LT-Debt-to-Total-Asset: 0.18 (As of Jan. 2026)


NSE:AVIENCE Avience Biomedicals Ltd NSE:AVIENCE
5 GF Score
Price ₹414.95
View Full Analysis

What is Avience Biomedicals LT-Debt-to-Total-Asset?

Avience Biomedicals NSE:AVIENCE 5 LT-Debt-to-Total-Asset is 0.18 as of Jan. 2026. GuruFocus rates NSE:AVIENCE with a GF Score™ of 5/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Avience Biomedicals's long-term debt to total assests ratio for the quarter that ended in Jan. 2026 was 0.18.

Avience Biomedicals's long-term debt to total assets ratio increased from . 20 (0.00) to Jan. 2026 (0.18). It may suggest that Avience Biomedicals is progressively becoming more dependent on debt to grow their business.

Avience Biomedicals  (NSE:AVIENCE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Avience Biomedicals LT-Debt-to-Total-Asset Related Terms

Avience Biomedicals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Avience Biomedicals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avience Biomedicals LT-Debt-to-Total-Asset Chart

Avience Biomedicals Annual Data
Trend Mar23 Mar24 Mar25
LT-Debt-to-Total-Asset
0.02 0.21 0.17

Avience Biomedicals Quarterly Data
Mar23 Mar24 Mar25 Jan26
LT-Debt-to-Total-Asset 0.02 0.21 0.17 0.18
NSE:AVIENCE
5GF Score
Avience Biomedicals Ltd NSE:AVIENCE
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avience Biomedicals LT-Debt-to-Total-Asset Calculation

Avience Biomedicals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (A: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2025 )/Total Assets (A: Mar. 2025 )
=98.496/565.246
=0.17

Avience Biomedicals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2026 is calculated as

LT Debt to Total Assets (Q: Jan. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jan. 2026 )/Total Assets (Q: Jan. 2026 )
=119.175/660.72
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.18 mean?
Avience Biomedicals (NSE:AVIENCE) has a LT-Debt-to-Total-Asset of 0.18 as of Jan. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Avience Biomedicals and its competitors.
Is Avience Biomedicals' LT-Debt-to-Total-Asset too high?
Avience Biomedicals' current LT-Debt-to-Total-Asset is 0.18. Overall, Avience Biomedicals has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' LT-Debt-to-Total-Asset compare to ABT and SYK?
Avience Biomedicals' LT-Debt-to-Total-Asset of 0.18 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Avience Biomedicals and its competitors. Avience Biomedicals's current LT-Debt-to-Total-Asset is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current LT-Debt-to-Total-Asset of 0.18. The current LT-Debt-to-Total-Asset is 0.18. Avience Biomedicals' overall GF Score™ is 5/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current LT-Debt-to-Total-Asset is 0.18 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avience Biomedicals Business Description

Address C-11, Block-C, Community Centre, Unit No-2, 1st Floor, Janakpuri A-3, New Delhi, IND, 110058
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
5GF Score

Get the complete analysis for NSE:AVIENCE

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹414.95
Price